Cruickshank D J, Fullerton W T, Klopper A
Br J Obstet Gynaecol. 1987 Jul;94(7):692-5. doi: 10.1111/j.1471-0528.1987.tb03177.x.
In a prospective study of 52 patients with ovarian malignancy followed up for 3-18 months the clinical significance of pre-operative serum CA 125 as a tumour marker was assessed. In 41 patients with epithelial ovarian cancer, the level of CA 125 correlated well with tumour load as indicated by FIGO stage. All epithelial histological types, including mucinous, released CA 125 although serous and undifferentiated tumours produced quantitatively more antigen. There was, however, no correlation between CA 125 concentration and histopathological grade, nor did CA 125 level appear to be of any prognostic value in epithelial ovarian cancer. Elevated CA 125 levels were also found in patients with sex cord/stromal tumours. Krukenberg tumours, an ovarian sarcoma and a serous carcinoma of low malignant potential.
在一项对52例卵巢恶性肿瘤患者进行3至18个月随访的前瞻性研究中,评估了术前血清CA 125作为肿瘤标志物的临床意义。在41例上皮性卵巢癌患者中,CA 125水平与国际妇产科联盟(FIGO)分期所示的肿瘤负荷密切相关。所有上皮组织学类型,包括黏液性肿瘤,均释放CA 125,尽管浆液性和未分化肿瘤产生的抗原量更多。然而,CA 125浓度与组织病理学分级之间无相关性,CA 125水平在上皮性卵巢癌中似乎也无任何预后价值。性索/间质肿瘤、库肯勃瘤、卵巢肉瘤和低恶性潜能浆液性癌患者中也发现CA 125水平升高。